Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Amyotrophic Lateral Sclerosis (ALS)

Progressive neurodegenerative disease affecting motor neurons. Cannabis has limited evidence for managing spasticity, sleep, pain, and appetite loss in ALS patients; no evidence to date demonstrates disease-modifying effects.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-05-15

Book Evaluation Call (833) LEGAL-MJ

NASEM evidence levelLimitedICD-10: G12.21

What is Amyotrophic Lateral Sclerosis (ALS)?

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that destroys motor neurons in the brain and spinal cord, leading to loss of voluntary muscle control. Symptoms typically include muscle weakness, spasticity, fasciculations, dysphagia, and respiratory compromise. Most patients survive 2–5 years from diagnosis.

There is no cure. FDA-approved treatments (riluzole, edaravone) modestly slow progression.

Does cannabis help Amyotrophic Lateral Sclerosis (ALS)?

The 2017 NASEM consensus report did not separately classify ALS-specific cannabis evidence, instead grouping it under the broader spasticity and pain categories where evidence is moderate to substantial. Small clinical studies and patient-reported surveys describe cannabis use for symptomatic management of:

Spasticity and muscle cramping
Sialorrhea (excess saliva)
Sleep disturbance
Pain
Appetite loss / cachexia

ALS is a qualifying condition under most US medical cannabis programs. Cannabis is not a disease-modifying treatment for ALS and should be coordinated with the patient's neurology and palliative care teams.

Eligibility

State eligibility for Amyotrophic Lateral Sclerosis (ALS)

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Amyotrophic Lateral Sclerosis (ALS): whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
State	Qualifies?	Program
Florida	Yes	Florida OMMU
Georgia	Yes	Georgia DPH Low-THC Registry
Texas	Yes	Texas Compassionate Use Program

Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

Does cannabis slow ALS disease progression?

No. There is no clinical evidence that cannabis or cannabinoids slow ALS progression. The role of cannabis in ALS is symptomatic (managing spasticity, sleep disturbance, pain, and appetite loss) not disease-modifying.

Which ALS symptoms have the strongest cannabis evidence?

Muscle spasticity has the most consistent evidence base, paralleling the stronger evidence for MS spasticity. Sleep disturbance, pain, and appetite stimulation have limited but suggestive evidence. Cannabis is most commonly used as adjunct symptomatic therapy alongside standard ALS medications.

Are there risks of cannabis specifically for ALS patients?

Yes. ALS patients with respiratory compromise should avoid inhaled cannabis. Cannabis can interact with riluzole and other ALS medications. Sedating effects can compound disease-related fatigue.

Is ALS a qualifying condition in most state medical-cannabis programs?

Yes. ALS is one of the most consistently enumerated qualifying conditions in US state medical-cannabis statutes, typically alongside terminal illnesses and severe neurodegenerative diseases.

Sources and citations

Ready to talk with a Miracle Leaf® physician?

Book Evaluation Call (833) LEGAL-MJ Shop Now

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.